HC Wainwright Predicts Weaker Earnings for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at HC Wainwright dropped their Q4 2026 earnings per share estimates for shares of Sanara MedTech in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.12 per share for the quarter, down from their prior estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, March 24th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). The company had revenue of $27.55 million during the quarter, compared to analysts’ expectations of $27.90 million. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%.

SMTI has been the subject of a number of other reports. Wall Street Zen upgraded shares of Sanara MedTech from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. Finally, Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sanara MedTech currently has a consensus rating of “Hold” and an average price target of $36.00.

Sanara MedTech Price Performance

Shares of NASDAQ SMTI opened at $17.24 on Friday. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95. The company has a debt-to-equity ratio of 7.75, a quick ratio of 1.59 and a current ratio of 1.80. The company has a 50 day simple moving average of $19.58 and a two-hundred day simple moving average of $23.96. The company has a market capitalization of $158.09 million, a price-to-earnings ratio of -4.08 and a beta of 1.10.

Hedge Funds Weigh In On Sanara MedTech

A number of institutional investors and hedge funds have recently made changes to their positions in SMTI. Rhumbline Advisers grew its position in Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after buying an additional 483 shares during the period. Geode Capital Management LLC raised its position in Sanara MedTech by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock worth $1,846,000 after acquiring an additional 546 shares during the period. State Street Corp boosted its stake in shares of Sanara MedTech by 1.1% during the 4th quarter. State Street Corp now owns 62,289 shares of the company’s stock worth $1,454,000 after acquiring an additional 690 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Sanara MedTech by 44.1% during the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after acquiring an additional 973 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after acquiring an additional 1,171 shares during the period. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.